# A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

> **NCT06732323** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 504 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** ESG401
- **DRUG:** Investigator's Choice Chemotherapy

## Key facts

- **NCT ID:** NCT06732323
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-04
- **Primary completion:** 2027-06
- **Final completion:** 2028-07
- **Target enrollment:** 504 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732323, "A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06732323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*